Key statistics
On Friday, Daiichi Sankyo Co Ltd (4568:TYO) closed at 4,435.00, 16.56% above the 52 week low of 3,805.00 set on Dec 21, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4,472.00 |
---|---|
High | 4,501.00 |
Low | 4,433.00 |
Bid | 4,434.00 |
Offer | 4,442.00 |
Previous close | 4,483.00 |
Average volume | 4.80m |
---|---|
Shares outstanding | 1.95bn |
Free float | 1.92bn |
P/E (TTM) | 34.26 |
Market cap | 8.73tn JPY |
EPS (TTM) | 130.86 JPY |
Annual div (ADY) | 60.00 JPY |
---|---|
Annual div yield (ADY) | 1.34% |
Div ex-date | Sep 27 2024 |
Div pay-date | Dec 10 2024 |
Data delayed at least 15 minutes, as of Nov 22 2024 06:30 GMT.
More ▼
- Daiichi Sankyo to Showcase TURALIO® Research in Patients with Tenosynovial Giant Cell Tumor at CTOS
- Datopotamab Deruxtecan New BLA Submitted for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
- ENHERTU® Receives Prestigious 2024 Prix Galien USA Award for Best Biotechnology Product
- Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
- ENHERTU® Granted Priority Review in the U.S. for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Who Have Received at Least One Line of Endocrine Therapy
- Datopotamab Deruxtecan Final Overall Survival Results Reported in Patients with Metastatic HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial
- Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer in HERTHENA-Lung02 Phase 3 Trial
- DS-9606 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors
- ENHERTU® Showed Substantial Clinical Activity in Patients with HER2 Positive Metastatic Breast Cancer and Brain Metastases
- Datopotamab Deruxtecan Showed Median Overall Survival of 14.6 Months in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
More ▼